Owkin Diagnostics Orb

AI Diagnostics

About our products

Clinically validated digital pathology AI to augment precision oncology workflows
Explore our products

Transform image into action with AI diagnostics

Slider
Significant patterns revealed at the tissue level
H&E
Lymphocytes

Our products enhance patient diagnostics in 3 key ways

Support pathologists

Provide quick and standard interpretation of H&E or IHC Whole Slide Images (WSIs).

Screen biomarkers

Prioritize patient cases for further molecular tests by predicting those most likely to have the biomarker.

Predict outcomes

Analyze the likelihood of survival, relapse, and response to treatment to better inform targeted treatment options.

RlapsRisk on-screen and tablet view showcasing risk assessment for breast cancer
Pictured here: RlapsRisk BC results in action. Image for presentation only.

First-in-class

Groundbreaking AI diagnostics, accessible across diverse workflows and IT settings

Speed icon
Faster than existing tests

Minutes vs weeks.

Scalable icon
Scalable

Software that runs on standard oncology data.

Seamless icon
Seamless integration

Platform agnostic and plug-and-play.

Cost icon
Cost saving

Compared with traditional tests.

Tissue icon
Tissue sparing

Multiple analyses possible with same tissue sample.

Reproducible icon
Reproducible

Standardized reports at the click of a button.

Explore our products

Our portfolio consists of products for clinical trials or research settings, and IVD solutions that are regulatory-approved and ready for use in clinical routine.
Filter selection
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Biomarker screening
MSIntuit GC
Optimize MSI testing for gastric cancer
MSIntuit GC
Digitized H&E
In development
Button
Biomarker screening
MSIntuit EC
Optimize MSI testing for endometrial cancer
MSIntuit EC
Digitized H&E
In development
Button
Biomarker screening
MSIntuit BTC
Optimize MSI testing for biliary tract cancer
MSIntuit BTC
Digitized H&E
In development
Button
Biomarker screening
MSIntuit SIC
Optimize MSI testing for small intestinal cancer
MSIntuit SIC
Digitized H&E
In development
Button
Outcome prediction
RlapsRisk BC
Assess the risk of relapse in early breast cancer
RlapsRisk BC
Digitized H&E
In development
Button
Biomarker screening
BRCAura BC
gBRCA testing for breast cancer
BRCAura BC
Digitized H&E
In development
Button
Biomarker screening
MSIntuit CRC
Optimize MSI testing for colorectal cancer
MSIntuit CRC
Digitized H&E
RUO* CE IVD
Button
Pathologist support
TLS Detect
Detect Tertiary Lymphoid Structures across tumor types
TLS Detect
Digitized H&E
RUO*
Button
*Certain products are labeled Research Use Only (RUO) or IVD for Performance Study Only (PSO) based on regional regulatory requirements.

How can you use our AI Dx?

Pharma
Match patients to approved drugs in clinical routine
Discover more
Button
Pharma
Accelerate patient identification for clinical trial enrollment
Discover more
Button
Clinicians & Labs
Optimize lab workflows with pathologist enhancements and case prioritization
Discover more
Button
Clinicians & Labs
Drive therapeutic decision making to improve patient outcomes
Discover more
Button

From data to approved medical device, we lead the field in AI diagnostic development

Prix Galien UK Winner 2024
Best Medical Technology

This award highlights Owkin’s dedication to enhancing the efficacy and precision of medical treatments, propelling them as a leader in the healthcare sector.

Read more
Button
GlobalData Winner Innovation -AI Diagnostics
Innovation -
AI Diagnostics

For integrating artificial intelligence to enhance diagnostic efficiency and accuracy, revolutionizing the traditional pathology workflow.

GlobalData Winner Product Launches - AI  Diagnostics
Product Launches - AI  Diagnostics

For significantly streamlining the diagnostic process by pre-screening, reducing the number of patients requiring standard MSI testing.

2024 Stevie® Winner for Technology Excellence
3 Stevie® Awards

Technology Breakthrough in Artificial Intelligence

Technology Breakthrough in Healthcare Technology

Grand Stevie for Highest-Rated Nomination of the year

Our building blocks for robust diagnostics

Select
Data
AI & Data Science
Regulatory & quality standards

Data

Our vast patient data network lays the foundation for impactful products that meet critical medical needs.
81
leading academic institutions and pathology labs with secured data access.
13
countries that ensure diverse cohorts.
33
therapeutic indications in oncology, immunology and inflammation, with leading KOLs in each field.

AI & data science

We are a world leader in AI and machine learning for digital pathology.
Interpretable
Breakthrough models built on a foundation of 8+ years of R&D with 59 tier 1 peer-reviewed articles.
Generalizable
Maximizing performance and generalizability with world-class foundation models and expertise in model fine-tuning.
Validated
Products undergo robust multicentric and international validations, across a variety of hardware and IT settings.

Regulatory and quality standards

Owkin has regulatory profficiency in navigating the new CE-IVDR and FDA frameworks.
Regulatory expertise
In-house quality management and niche experience in developing AI as fully approved IVDs for clinical use.
International security standards
Robust infrastructure to obtain and maintain ISO certifications.
Notified bodies
Audited by French health authorities certified (ANSM). GMED is our notified body.
View our KOL network map
From Slide to Device
White Paper

From Slide to Device

Our white paper on the transformative potential of AI in pathology

We explore the opportunities and challenges of integrating AI into digital pathology workflows.

Button
State of the Nation
Report

State of the Nation

Opportunities and Challenges for Digital Pathology and AI Solutions

The evolving landscape of digital pathology and AI in healthcare across the US, UK, and France.

Button
Images shown may represent the range of products, or be for illustration purposes only, and may not be an exact representation of the product.
Information last updated on 18th March 2025.